New gene silencing therapy for cervical cancerNovember 17, 2005Researchers at The University of Queensland's (UQ) Centre for Immunology and Cancer Research (CICR), based at the Princess Alexandra Hospital, have pioneered a new approach for the treatment of cervical cancer. Lead researcher Dr Nigel McMillan said the finding was based on the method of "gene silencing", a novel technique to target and turn off single genes in a cell. "Our research shows not only can we stop cervical cancer cells from growing in the test tube, but we can also completely eliminate the formation of cancer tumours in animal models," Dr McMillan said.
Professor Ian Frazer, Director of the CICR and developer of a vaccine for cervical cancer, said the research represented a significant step towards developing gene therapy for cervical cancer. Cervical cancer is the leading cause of cancer death in women aged 25-50 worldwide and causes around 300 deaths per year in Australia. Cervical cancer is caused by infection with the human papillomavirus and is the result of the over-production of two viral cancer-causing genes called E6 and E7. The research team was able to turn off the production of these genes in cancer cells, resulting in the death of the cancer. "Because these viral genes are foreign we can treat normal cells and they remain unaffected by our treatment," Dr McMillan said. "Development of treatments for humans would be an advance over the current treatments, radiation and chemotherapy, which kill not only cancer cells but also normal cells that leads to hair loss and nausea. "We envisage such treatment will be used for all forms of cervical cancer including the premalignant lesions picked up by the pap smear and especially for advanced cervical cancers where the cancer has moved to other sites such as the lung or liver.\\\ Research Australia | |||||||||||||||||||||
|
Related Cervical Cancer News Articles Cervical cancer prevention should focus on vaccinating adolescent girls The cost-effectiveness of vaccination in the United States against human papillomavirus (HPV), a sexually-transmitted virus that causes cervical cancer, will be optimized by achieving universal vaccine coverage in young adolescent girls, by targeting initial "catch-up" efforts to vaccinate women younger than 21 years of age, and by revising current screening policies. Breaking the 'mucus barrier' with a new drug delivery system Chemical engineers from Johns Hopkins University have broken the "mucus barrier," engineering the first drug-delivery particles capable of passing through human mucus - regarded by many as nearly impenetrable - and carrying medication that could treat a range of diseases. Those conditions include lung cancer, cervical cancer and cystic fibrosis, the research noted in a presentation scheduled for the 236th National Meeting of the American Chemical Society. Novel structure proteins could play a role in apoptosis Isoforms from Novel Structure Proteins (NSP), a new family of genes discovered by researchers in the Sbarro Institute for Cancer Research and Molecular Medicine in Temple University's College of Science and Technology, could be involved in apoptosis or programmed cell death. Obese women in Canada are less likely to be screened for cervical cancer Research in the United States has shown that obese people are less likely than their normal-weight peers to undergo screening for breast, colon and cervical cancer. Raj Padwal, Rebecca Mitchell and Scott Klarenbach, from the University of Alberta's Faculty of Medicine & Dentistry, have undertaken a study to see if this trend is also true in Canada. New study shows potential to treat or prevent viral cancers A new study, presented at the SNM 55th Annual Meeting, shows that radioimmunotherapy (RIT) targeting viral antigens offers a novel option to treat-or even prevent-many viral cancers by targeting cancer cells expressing viral antigens or infected cells before they convert into malignancy. Avoiding Spleen Removal for Cooley's Anemia Sufferers Researchers from Weill Cornell Medical College may have discovered the precise role of a gene in one of the world's most common blood disorders, beta-thalassemia, commonly known as Cooley's anemia. Estrogen Helps Drive Distinct, Aggressive Form of Prostate Cancer Using a breakthrough technology, researchers led by a Weill Cornell Medical College scientist have pinpointed the hormone estrogen as a key player in about half of all prostate cancers. UNC study firms up promise of potential new cervical cancer screening tool New research into the causes of cervical cancer appears to lend weight to the promise of a potential early detection method that could help prevent the disease. Mothers less likely to pursue HPV vaccination for youngest daughters Because the first national study of its kind has found that U.S. mothers report they are less likely to vaccinate daughters under age 13 against human papillomavirus virus (HPV), even though the vaccine is recommended for girls at age 11 and 12, it's incumbent upon the healthcare community to work to improve mom's acceptance of the vaccination for younger daughters, say researchers at Cincinnati Children's Hospital Medical Center who conducted the study. HPV is a sexually transmitted virus known to cause cervical cancer. Viruses may play a role in lung cancer development Papers presented at the 1st European Lung Cancer Conference, jointly organized by the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) in Geneva, Switzerland highlight emerging evidence that common viruses may contribute to the development of lung cancer. More Cervical Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||